Bispecific Antibodies for Targeting Alzheimer's Disease in the Brain
This patent describes special antibodies designed to cross into the brain and target amyloid-beta, a protein linked to Alzheimer's disease.
Original patent title: “Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use”
This patent describes special antibodies designed to cross into the brain and target amyloid-beta, a protein linked to Alzheimer's disease. Granted in 2026.
Coverage
What does this patent actually cover?
This patent describes special antibodies that are 'bispecific,' meaning they are engineered to attach to two different targets at the same time. One target is human A-beta, a protein linked to Alzheimer's disease. The other target is the human transferrin receptor, a protein found on the blood-brain barrier, which is the protective shield around the brain. The patent provides these specific antibodies and methods for using them, likely to help deliver treatment to the brain for conditions like Alzheimer's disease.
The gap
What does this patent NOT cover?
- Antibodies that only target one specific protein (monospecific antibodies), rather than two different ones simultaneously.
- Bispecific antibodies that target different combinations of proteins, not specifically human A-beta and the human transferrin receptor.
- Methods of treating Alzheimer's disease that do not involve using antibodies to cross the blood-brain barrier via the transferrin receptor.
- Other types of treatments for neurodegenerative diseases, such as small molecule drugs or gene therapies, that are not antibody-based.
- Antibodies that target A-beta but do not use the transferrin receptor to enter the brain.
- Antibodies that target the transferrin receptor but do not also target A-beta.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever part is designing a single antibody that can both sneak past the brain's defenses using the transferrin receptor and then specifically attack the amyloid-beta proteins associated with Alzheimer's disease.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Antibody-based therapies for neurodegenerative diseases
Drugs designed to cross the blood-brain barrier
Next-generation Alzheimer's treatments
Why it matters
The bigger picture
Alzheimer's disease affects millions, and a major challenge in treating it is getting medicines past the blood-brain barrier, a natural defense that protects the brain. This type of antibody aims to overcome that barrier, potentially opening new ways to deliver treatments directly to the brain to target amyloid-beta plaques.
Filed
April 10, 2023
Granted
September 15, 2026
Market context
Who's building on this
Companies in this space
Major pharmaceutical companies like Eli Lilly, Biogen, and Roche, along with numerous biotech startups, are actively researching and developing antibody-based therapies for Alzheimer's disease, including strategies to overcome the blood-brain barrier.
Market impact
This technology could significantly impact the market for neurodegenerative disease treatments by enabling more effective drug delivery to the brain. If successful, it could lead to new classes of therapeutics that bypass the current limitations of getting drugs past the blood-brain barrier, potentially offering better outcomes for patients with Alzheimer's disease.
Claim 1 — Plain English
What this patent covers
This patent describes special antibodies that are 'bispecific,' meaning they are engineered to attach to two different targets at the same time. One target is human A-beta, a protein linked to Alzheimer's disease. The other target is the human transferrin receptor, a protein found on the blood-brain barrier, which is the protective shield around the brain. The patent provides these specific antibodies and methods for using them, likely to help deliver treatment to the brain for conditions like Alzheimer's disease.
The clever bit
The clever part is designing a single antibody that can both sneak past the brain's defenses using the transferrin receptor and then specifically attack the amyloid-beta proteins associated with Alzheimer's disease.
What it does not cover
- Antibodies that only target one specific protein (monospecific antibodies), rather than two different ones simultaneously.
- Bispecific antibodies that target different combinations of proteins, not specifically human A-beta and the human transferrin receptor.
- Methods of treating Alzheimer's disease that do not involve using antibodies to cross the blood-brain barrier via the transferrin receptor.
- Other types of treatments for neurodegenerative diseases, such as small molecule drugs or gene therapies, that are not antibody-based.
- Antibodies that target A-beta but do not use the transferrin receptor to enter the brain.
- Antibodies that target the transferrin receptor but do not also target A-beta.
Patent timeline
Application submitted to the patent office
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
0/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$36K – $115K
Midpoint $72K · 16.5 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
Concepts involved
Cite this patent
(2026). Bispecific Antibodies for Targeting Alzheimer's Disease in the Brain (U.S. Patent No. 12,735,497). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12735497/bispecific-anti-human-a-betahuman-transferrin-receptor-antibodies-and-methods
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12735497"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Bispecific Antibodies for Targeting Alzheimer's Disease in the Brain cover?
This patent describes special antibodies designed to cross into the brain and target amyloid-beta, a protein linked to Alzheimer's disease.
When does this patent expire?
This patent is expected to expire on September 15, 2046, when the invention enters the public domain.
What problem does this patent solve?
Alzheimer's disease affects millions, and a major challenge in treating it is getting medicines past the blood-brain barrier, a natural defense that protects the brain. This type of antibody aims to overcome that barrier, potentially opening new ways to deliver treatments directly to the brain to target amyloid-beta plaques.
What does this patent NOT cover?
Antibodies that only target one specific protein (monospecific antibodies), rather than two different ones simultaneously.
Patent monitoring